A practical reference on GHRH analog: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-05-25. Anything still debated is marked as such rather than presented as settled.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Identity and purity are judged through a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact peptide from truncated, oxidized, and deamidated variants, and the resulting peak-area percentages yield a purity figure. Electrospray ionization mass spectrometry confirms the expected molecular mass and can expose unanticipated modifications. Amino acid analysis and peptide mapping support sequence fidelity, while water content, pH, sterility, and bacterial endotoxin testing describe the physical and microbiological attributes of a finished lot.
Regulatory position depends on jurisdiction and on the form in which the material is sold. A branded product holds approval in the United States for a defined indication, and prescribing is confined to that label. Material marketed for laboratory research is not evaluated for human use and carries no such clearance. Independent verification therefore rests on certificates of analysis, third-party testing, and documented chain of custody. The substance also appears on the World Anti-Doping Agency prohibited list within the category covering growth hormone-releasing factors.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide | GHRH analog family |
| Residue count | 44 amino acids | Matches human GHRH(1-44) backbone |
| N-terminal group | trans-3-hexenoyl | Main structural difference from native hormone |
| Appearance | White to off-white powder | Lyophilized solid form |
| Solubility class | Freely soluble in water | Peptide character; less soluble in organic solvents |
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Stimulated growth hormone release leads to hepatic production of insulin-like growth factor 1, a key mediator of many growth hormone effects. In clinical studies, tesamorelin increased IGF-1 levels in a dose-dependent manner, although the response varies among individuals. The drug's effect on visceral fat is thought to involve growth hormone-mediated lipolysis and altered adipocyte metabolism. Muscle mass and lean body mass have also been assessed as secondary outcomes, but changes are generally smaller and less consistent than fat reductions.
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone (GHRH) family. Its sequence corresponds to the fully active 44-amino-acid form of human GHRH, with a single structural modification: the addition of a trans-3-hexenoyl group at the N-terminus. That modification is not found in the naturally occurring hormone and was introduced deliberately during development to improve stability against enzymatic degradation. The compound is therefore best described as a stabilized analogue rather than a naturally occurring peptide.
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
Researchers reported numerous "chemical strains" or chemotypes: lichens identical in appearance yet separable by their metabolites. For instance, MacKenzie (1951) noted that morphologically identical Stereocaulon tomentosum forms differed in chemistry—one containing stictic acid, the other fumarprotocetraric acid. These chemotypes often occupy different regions or microhabitats, and breeding or DNA data have since supported treating them as separate species. Metabolite profiles also informed higher-level classification. In some cases, entire genera were defined or redefined by their chemical profiles. In the Cetraria group, species rich in specific fatty acids were placed in Platismatia, whereas taxa containing orcinol depsidones were transferred to Cetrelia; the shift was consistent with their chemical differences. Chemical data further resolved misclassifications based solely on morphology. For example, species formerly combined in Anaptychia were divided after researchers noted that forms with thick-walled spores and a medulla containing zeorin plus specific depsidones formed a coherent group (Heterodermia), whereas thin-walled, chemically simpler taxa stayed in Anaptychia.
== Contribution to radioactivity of reprocessed uranium == The half-life of 238U is about 190 times as long as that of 236U; therefore, 236U has about 190 times as much specific activity. Thus, in reprocessed uranium with 0.5% 236U, the 236U and 238U will produce about the same level of radioactivity. (235U contributes only a few percent.) The ratio is less than 190 when the decay products of each are included. The decay chain of uranium-238 to uranium-234 and eventually lead-206 involves emission of eight alpha particles in a time (hundreds of thousands of years) short compared to the half-life of 238U; so a sample of 238U in equilibrium with its decay products (as in natural uranium ore) has eight times the alpha activity of 238U alone. Even purified natural uranium where the post-uranium decay products have been removed, contains an equilibrium quantity of 234U and therefore about twice the alpha activity of pure 238U. Enrichment to increase 235U content will increase 234U to an even greater degree, and roughly half of this 234U will survive in the spent fuel. On the other hand, 236U decays to thorium-232 which has a half-life of 14 billion years, much longer than its own; so its decay chain effectively stops after one step even at long timescales; and the fact that it is an alpha decay means the external exposure hazard is negligible compared to the natural isotopes.
== Genes == There are two major forms of the GNRHR, each encoded by a separate gene (GNRHR and GNRHR2). Alternative splicing of the GNRHR gene, GNRHR, results in multiple transcript variants encoding different isoforms. More than 18 transcription initiation sites in the 5' region and multiple polyA signals in the 3' region have been identified for GNRHR.
In late 1918, Poles hoping for a sovereign Poland started serious preparations for an uprising after Wilhelm II's abdication on 9 November 1918, which marked the end of the German Empire. The monarchy was replaced by the Weimar Republic. The uprising broke out on 27 December 1918 in Poznań, after a patriotic speech by Ignacy Paderewski, the famous pianist, who would become the Polish prime minister in 1919, with 2,000 men serving in the Guard and Security Service rising up in the city. The insurrectionist forces consisted of members of the Polish Military Organization, who formed the Straż Obywatelska (Citizen's Guard), later renamed as Straż Ludowa (People's Guard), which included many volunteers, who were mainly veterans of World War I. The first contingent to reach the Bazar Hotel, from where the uprising was initiated, was a 100-strong force from wildecka kompania Straży Ludowej (Wilda's People's Guard) led by Antoni Wysocki. The ruling body was the Naczelna Rada Ludowa (Supreme People's Council). Initially, the members of the council, including Captain Stanisław Taczak and General Józef Dowbor-Muśnicki were against the uprising, but they changed their minds in support of the insurrection on 9 January 1919. The timing was advantageous for the insurrectionists since between late 1918 and early 1919, internal conflict had weakened Germany, and many of its soldiers and sailors engaged in mutinous actions against the state. Demoralized by the signing of the armistice on 11 November 1918, the new German government was further embroiled in subduing the German Revolution.
Sources: en.wikipedia.org
In it Adorno not only deviated from the theoretical program Horkheimer had laid out a year earlier but also challenged philosophy's very capacity for comprehending reality as such: "For the mind," Adorno announced, "is indeed not capable of producing or grasping the totality of the real, but it may be possible to penetrate the detail, to explode in miniature the mass of merely existing reality." In line with Benjamin's The Origin of German Tragic Drama and preliminary sketches of the Arcades Project, Adorno likened philosophical interpretation to experiments that should be conducted "until they arrive at figurations in which the answers are legible, while the questions themselves vanish." Having lost its position as the Queen of the Sciences, philosophy must now radically transform its approach to objects so that it might "construct keys before which reality springs open." Following Horkheimer's taking up the directorship of the Institute, a new journal, Zeitschrift für Sozialforschung, was produced to publish the research of Institute members both before and after its relocation to the United States. Though Adorno was not an Institute member, the journal published many of his essays, including "The Social Situation of Music" (1932), "On Jazz" (1936), "On the Fetish-Character in Music and the Regression of Listening" (1938), and "Fragments on Wagner" (1938).
== History == Glutathione reductase was first purified in 1955 at Yale University by P. Janmeda. Janmeda also identified NADPH as the primary electron donor for the enzyme. Later groups confirmed the presence of FAD and the thiol group, and an initial mechanism was suggested for the mechanism in 1965. The initial (low resolution) structure of glutathione reductase was solved in 1977. This was quickly followed by a 3Å structure by Shulze et al. in 1978. Glutathione reductase has been studied exhaustively since these early experiments, and is subsequently one of the most well characterized enzymes to date.
This product is then treated with acryloyl chloride. The initial step in this case probably involves the acylation of nitrogen on the enamine; conjugate addition then completes the formation of the lactam ring. Treatment of that product with triethyl silane then reduces the ring unsaturation and cleaves the benzylic nitrogen bond on the auxiliary to yield as the optically pure trans isomer. Displacement of bromine with the mercapto benzthiazole completes the synthesis of izonsteride.
== Career == Bentley dropped out of high school to pursue his own acting career, and had practiced autographs by the age of 12. He had to take odd jobs in movie theaters, a fish market, and a grocery store, among other places as he waited for his big break. His appearance enabled him to play the part of teens even into his twenties, and he landed a variety of small parts in television series and movies before landing bigger roles. Debuting in a 1986 Starburst commercial, he began his career as a child actor appearing in television commercials and guest spots on various television series before landing a role on the short-lived but critically acclaimed television series South Central in 1994. His first feature film role came in the 1995 horror movie Tales from the Hood, about the inner-city ganglands, an anthology of four stories focused on the consequences of the gang lifestyle. In that particular film, he played Crazy K, a cold and angry character. He once played a teenage father who opted to stay home with his child instead of turn out for the high school football team in a public service television announcement. In 1995, South Central creator Ralph Farquhar cast Bentley in the series Moesha as Hakeem Campbell, the always hungry friend of Moesha, which ran for six seasons on UPN. After Moesha ended, Bentley continued acting while pursuing a career as a rapper in the highly anticipated recording group UPRIZE with Marché Meeks aka "Cartier" and Tyson Pearson "Typhoon". In 2001, he appeared as C-Money in The Wash opposite Dr. Dre and Snoop Dogg.
==== Others ==== Monophosphoryl lipid A (MPL), a detoxified version of the lipopolysaccharide toxin from the bacterium Salmonella Minnesota, interacts with the receptor TLR4 to enhance immune response. Several unmethylated cytosine phosphoguanosine (CpG) oligonucleotides activate the TLR9 receptor that is present in a number of cell types of the immune system. The adjuvant CpG 1018 is used in an approved Hepatitis B vaccine. The adjuvant Matrix-M is an immune stimulating complex (ISCOM; a specific patented kind of liposome) consisting of nanospheres made of QS-21, cholesterol and phospholipids. It is used in the approved Novavax Covid-19 vaccine and in the malaria vaccine R21/Matrix-M.
Sources: en.wikipedia.org
No. It is a peptide that acts upstream of growth hormone release, while growth hormone is the hormone itself. The two differ in size, in receptor, and in how the body clears them.
It blocks the amino-terminal degradation step that limits native GHRH. The addition extends how long the peptide survives in plasma without removing its ability to activate the receptor.
The chain contains 44 amino acid residues. It matches the human GHRH(1-44) sequence apart from the amino-terminal modification.
Reconstituted solutions are kept cold and used within the period stated on the label or certificate. Repeated warming and cooling cycles should be avoided because they encourage aggregation and gradual loss of potency.